Good
Mostly Aligned
Patient Risk:
Low
Summary
All enumerated safety/contraindication claims are supported by the provided FDA label excerpts (Sections 4, 5.1, 5.2, 5.3, and part of Section 2). However, the evaluation is incomplete because several label elements (e.g., boxed warning text, detailed dosage instructions, drug interactions, and broader administration/monitoring/storage content) were not provided in the excerpts.
Category Scores
Accurate Statements
Increases risk of endometrial cancer when used as unopposed estrogen therapy in a woman with a uterus.
Supported by 5.2 Malignant Neoplasms: increased risk with unopposed estrogen in women with a uterus.
Adding a progestin to postmenopausal estrogen therapy reduces the risk of endometrial hyperplasia (a precursor to endometrial cancer).
Supported by 5.2 Malignant Neoplasms (progestin reduces risk of endometrial hyperplasia). Also consistent with Section 2 text provided: progestin should be considered to reduce risk of endometrial cancer.
Increases cardiovascular thromboembolic risk (stroke and DVT with estrogen-alone; PE, DVT, stroke, and MI with estrogen plus progestin).
Supported by 5.1 Cardiovascular Disorders.
Increased risk of invasive breast cancer with estrogen plus progestin therapy (CE + MPA) in the WHI substudy.
Supported by 5.2 Malignant Neoplasms: increased risk in WHI estrogen plus progestin substudy with CE + MPA.
Estrogen-alone therapy in WHI was not associated with increased risk of invasive breast cancer.
Supported by 5.2 Malignant Neoplasms: WHI estrogen-alone substudy not associated with increased risk of invasive breast cancer.
Estrogen therapy increases risk of probable dementia in older women in WHIMS.
Supported by 5.3 Probable Dementia.
PREMARIN is contraindicated in breast cancer or history of breast cancer (with limited exception).
Supported by 4 Contraindications: breast cancer or history of breast cancer except appropriately selected patients for metastatic disease.
PREMARIN is contraindicated in active DVT/PE or history of these conditions.
Supported by 4 Contraindications.
PREMARIN is contraindicated in active arterial thromboembolic disease (for example stroke and MI) or history of these conditions.
Supported by 4 Contraindications.
Unsupported Statements
Contradictions
Important Omissions
Boxed warning verification and full boxed-warning content were not confirmed because boxed-warning text was not included among the provided label excerpts.
Importance:
Moderate
Broader label items not assessed in the excerpts provided (e.g., detailed dosing regimen, specific administration instructions, drug interactions, monitoring instructions, and storage/handling) cannot be evaluated for alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI claims evaluated here are limited to risks/contraindications that are explicitly supported by the provided label excerpts. No contradictions or unsupported risk claims were identified based on the supplied text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Evaluation completeness is limited to the provided excerpts; boxed warning content and other label sections (interactions, detailed dosing/administration, monitoring, storage) were not available for verification.
Suggested Improvement
If available, provide the full prescribing information (or additional relevant sections) so boxed warning language, dosage/administration details, drug interactions, and monitoring/storage content can be checked for alignment.